Russia Says Sputnik V Vaccine 92% Effective Against Coronovirus

Russia registered Sputnik V for public use in August, the first country to do so. (File)

Moscow:

Russian Sputnik V vaccine is 92 percent effective in protecting people from COVID-19, the country’s sovereign wealth fund said on Wednesday, as Moscow kept pace with Western dragmakers in the shooting race, according to the results of the interim test. Courses for

The preliminary results are only the second such vaccine to be released globally from human trials that could have prevented an epidemic that has killed more than 1.2 million people and devastated the world. Mondial economy.

Russia registered Sputnik V for public use in August, the first country to do so, although approval came before mass testing began in September.

Interim results are based on data from the first 16,000 trial participants to receive two injections of the two-dose vaccine, the Russian Direct Investment Fund (RDIF), which backs the vaccine and markets it globally. global.

The so-called third phase of the shooting, developed by the Gamelea Institute, is currently being tested in 29 clinics across Moscow and will involve a total of 40,000 volunteers, a quarter of whom will receive a placebo.

The RDIF said the chance of contracting Cotview-19 was 92% lower than those vaccinated with Sputnik V.

This exceeds the 50% efficacy limit for COVID-19 vaccines prescribed by the United States Food and Drug Administration.

“We are showing, based on the data, that we have a very effective vaccine,” said Kirill Dimrick, head of RDIF, adding that the news is that the developers of the vaccine will one day speak with their grandchildren.

Russia’s announcement quickly follows results released Monday by vaccine developers Pfizer Inc and BioNTech, who said their injection was also over 90% effective.

Pfizer and Bayonet Vaccine uses messenger RNA (mRNA) technology and is designed to trigger an immune response without the use of pathogens, such as real viral particles.

The Sputnik V vaccine is designed to respond with two injections for up to 21 days based on 21 different viral vectors that cause the common cold: the human adenoviruses Ad5 and Ad26.

(Except for the title, this story was not edited by NDTV employees and posted from a syndicated feed.)

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: